The report forecasts the global lung cancer therapeutics market to contribute around $11.19 billion during the period 2016-2020.
The report has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
The market has witnessed the emergence of nanomedicine, which is likely to have a positive impact on the market. The lipid-based nanoparticles and polymer-based approaches for the drug delivery are gaining traction in the market, owing to the limitations of current technologies. The existing technologies need numerous cells to detect the presence of a tumor. On the other hand, nanotechnology approach could radically lower this requirement, allowing much earlier diagnosis or treatment regimes.
According to the report, the market has been witnessing an increased demand for immune-based therapies such as checkpoint inhibitors. There are various types of checkpoint inhibitors that target different checkpoints on immune cells. These treatments work by allowing to mount a stronger and effective attack against lung cancer. The traditional chemotherapy approach involves the destruction of cancerous cells as well as nearby benign cells. This will create a lot of side effects and affects the patient compliance.
Further, the report states that the growing popularity of alternative therapeutics are expected to hinder growth prospects in the market. With the increasing side effects of conventional drugs, the individuals are seeking for alternative therapeutics. The increased demand for these therapies is also due to the high cost of lung cancer therapeutics. Some of the alternative therapeutics include mind and body medicines, biology-based practices, energy work, and whole medical systems.